2021
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal Of Cancer 2021, 162: 221-236. PMID: 34980502, PMCID: PMC9554673, DOI: 10.1016/j.ejca.2021.09.046.Peer-Reviewed Original ResearchConceptsPeptide radionuclide receptor therapyProphylactic neck irradiationDisease-free survivalOlfactory neuroblastomaSomatostatin receptor 2Stable diseaseAdjuvant radiotherapyNeck irradiationOverall survivalReceptor 2Potential efficacyPeptide receptor radionuclide therapyReceptor radionuclide therapyMultivariable survival analysisPertinent clinical dataClinical trial dataKey prognostic markersNodal recurrenceClinical outcomesClinicopathological characteristicsT stagePrognostic valueReceptor therapyDisease stageNeuroblastoma patientsSinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm.
Al-Jobory YM, Pan Z, Manes RP, Omay SB, Ikuta I. Sinonasal Glomangiopericytoma: Review of Imaging Appearance and Clinical Management Update for a Rare Sinonasal Neoplasm. The Yale Journal Of Biology And Medicine 2021, 94: 593-597. PMID: 34970096, PMCID: PMC8686777.Peer-Reviewed Original ResearchConceptsWorld Health OrganizationParanasal sinusesNasal cavityClinical management updateRare sinonasal neoplasmSlight female predominanceLow malignant potentialComplete surgical excisionNon-specific appearanceCase of glomangiopericytomaDecade of ageAggressive treatmentExcellent prognosisSinus massFemale predominanceLocal excisionLocal recurrenceMale patientsSurgical excisionRare tumorMalignant potentialImaging appearancesSinonasal neoplasmsSinonasal cavityTumor extent
2019
Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach
Torabi SJ, Spock T, Cardoso B, Chao J, Morse E, Manes RP, Judson BL. Margins in Sinonasal Squamous Cell Carcinoma: Predictors, Outcomes, and the Endoscopic Approach. The Laryngoscope 2019, 130: e388-e396. PMID: 31755988, DOI: 10.1002/lary.28315.Peer-Reviewed Original ResearchConceptsSinonasal squamous cell carcinomaHigh-volume facilitiesNational Cancer DatabaseSquamous cell carcinomaPositive marginsOverall survivalSurgical approachMargin statusCell carcinomaEthmoid sinusEndoscopic approachMultivariable binary logistic regressionDecreased overall survivalHigher T stageBinary logistic regressionAdditional therapySelect patientsAdult patientsEndoscopic treatmentMultivariable analysisSurgical managementT stageTherapy administrationDifferentiated tumorsOpen surgery
2012
Ossifying fibroma of the nose and paranasal sinuses
Manes RP, Ryan MW, Batra PS, Mendelsohn D, Fang YV, Marple BF. Ossifying fibroma of the nose and paranasal sinuses. International Forum Of Allergy & Rhinology 2012, 3: 161-168. PMID: 22736440, DOI: 10.1002/alr.21067.Peer-Reviewed Original Research